Oncopeptides
4.57 SEK
-2.14 %
Less than 1K followers
ONCO
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Investor consensus
-2.14 %
-4.89 %
-14.26 %
-15.53 %
+51.50 %
+208.80 %
-44.01 %
-95.98 %
-84.18 %
Oncopeptides is a biotechnology company developing drugs for difficult-to-treat hematological diseases. The company uses its PDC platform to develop peptide-linked drugs that selectively deliver cytotoxic agents into cancer cells. The company has drugs for commercialization, and has several drug candidates in development. Oncopeptides was founded in 2000 and is headquartered in Stockholm.
Read moreMarket cap
1.25B SEK
Turnover
10.15M SEK
Revenue
31.65M
EBIT %
-895.73 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
Revenue M
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
19/2
2026
Annual report '25
13/5
2026
Interim report Q1'26
21/5
2026
General meeting '26
All
Webcasts
Press releases
3rd party
ShowingAll content types
Research shows that Pepaxti is effective in high-risk myeloma
Oncopeptides har utsett valberedningen
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
